Compare Organon & Co. Common Stock (OGN) vs Snowflake Inc (SNOW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Organon & Co. Common Stock vs Snowflake Inc — how do they compare? Organon & Co. Common Stock trades at $13.58 (market cap $3.62B), while Snowflake Inc trades at $330.3 (market cap $126.22B). The key difference: Snowflake Inc is far larger — about 34.9× Organon & Co. Common Stock's market cap, and Organon & Co. Common Stock pays a 0.58% dividend while Snowflake Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Organon & Co. Common Stock for 0 Days and Snowflake Inc for 53 Days on average.
| OGN | SNOW | |
|---|---|---|
Market Cap | $3.62B | $126.22B |
Volume | 2,892,999 | 4,112,138 |
Sector | Health | Technology |
52-Week High | $13.81 | $368.89 |
52-Week Low | $5.70 | $121.11 |
Typical Hold Time | 0 Days | 53 Days |
Enterprise Value | $11.04B | $126.64B |
Dividend Yield | 0.58% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Organon (OGN) trades at $13.77, showing no change in the latest session. The stock demonstrates strong profitability with 52.68% gross margins and 24.04% ROE, though recent quarterly earnings have missed expectations. Valuation appears reasonable with P/E of 17.65 and P/S of 0.59. The company shows positive cash flow trends with 2026 projections indicating $533M net cash flow. Recent FDA developments for MIUDELLA and VTAMA products highlight ongoing pipeline progress.
OGN presents a mixed outlook with solid fundamentals offset by earnings misses. The healthcare company's improving cash flow and product pipeline offer potential upside, but investor sentiment remains divided with analysts showing cautious optimism. Key risks include execution challenges and competitive pressures in the pharmaceutical sector.
Snowflake (SNOW) trades at $335.08, down 7.02% amid market volatility, but maintains strong analyst support with 81% buy ratings and a $418.03 consensus target. The company shows robust revenue growth, reaching $3.63 billion in 2025, though it remains unprofitable with a -20.07% net margin. Recent technical indicators are bullish on moving averages, while oscillators remain neutral. Key developments include a $3.75 billion convertible note offering and expanded partnerships with UiPath.
Outlook remains positive given strong revenue trajectory and analyst confidence, but risks include persistent losses, high valuation multiples (P/S 22.66), and competitive pressures. The stock offers growth potential if profitability improves, yet investors must weigh execution risks against long-term AI data cloud opportunities.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Organon & Co. Common Stock
Organon & Co. is a global healthcare company focused on women's health, biosimilars, and established brands, spun off from Merck & Co. in 2021. Its portfolio of more than 70 medicines includes contraception and fertility therapies, immunology and oncology biosimilars, and treatments in cardiovascular, respiratory, and dermatology, distributed in over 140 countries.
Read more on OGN →About Snowflake Inc
Founded in 2012, Snowflake is a data lake, warehousing, and sharing company that came public in 2020. To date, the company has over 3,000 customers including nearly 30% of the Fortune 500 as its customers. Snowflake's data lake stores unstructured and semistructured data that can then be used in analytics to create insights stored in its data warehouse. Snowflake's data sharing capability allows enterprises to easily buy and ingest data almost instantaneously compared with a traditionally months-long process. Overall, the company is known for the fact that all of its data solutions that can be hosted on various public clouds.
Read more on SNOW →
